Solidarity trial

Solidarity trial
Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific · CC BY-SA 4.0 · source
Name	Solidarity trial
Sponsor	World Health Organization
Collaborators	European Commission, Médecins Sans Frontières, Oxford University
Location	Global
Start date	2020
Status	Completed
Phase	Adaptive, open-label

Solidarity trial

The Solidarity trial was a multi-country, adaptive, randomized clinical trial coordinated by the World Health Organization that evaluated repurposed antiviral and adjunctive treatments for COVID-19 pandemic patients across multiple healthcare facility settings. Launched in 2020, the initiative leveraged global networks including the European Commission, Médecins Sans Frontières, and academic partners such as University of Oxford to rapidly generate pragmatic evidence on interventions under emergency conditions. The trial’s design prioritized simplicity, scalability, and real-world applicability, enrolling tens of thousands of patients in resource-diverse regions including Brazil, South Africa, India, Spain, and Canada.

Background and Rationale

The trial emerged amid the early phase of the COVID-19 pandemic when candidate therapeutics such as remdesivir, lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1a were proposed based on in vitro activity, observational cohorts, and experience from Ebola virus epidemic in West Africa. Urgent public health priorities underscored by organizations like the World Health Organization and recommendations from the World Health Assembly motivated a collaborative, large-scale randomized evaluation to overcome limitations noted in small trials from institutions such as Cleveland Clinic and Johns Hopkins University. The Solidarity approach reflected adaptive platform strategies previously discussed in the context of adaptive clinical trial, RECOVERY trial, and initiatives led by National Institutes of Health and Coalition for Epidemic Preparedness Innovations.

Trial Design and Methods

Solidarity used an adaptive, open-label, randomized platform model enabling rapid adding or dropping of treatment arms, consistent with guidance from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and ethics frameworks like the Declaration of Helsinki. Core features included centralized data collection, simplified consent procedures aligned with World Medical Association standards, and an intention-to-treat analysis plan informed by statisticians associated with University of London and Harvard T.H. Chan School of Public Health. Randomization schemes balanced between standard of care and active arms across heterogeneous sites including tertiary centers such as Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo and district hospitals in Kenya. Outcomes were prespecified, focusing on in-hospital mortality, initiation of ventilation, and duration of hospitalization, with interim analyses overseen by an independent data safety monitoring board constituted from experts affiliated with European Medicines Agency and Food and Drug Administration.

Interventions and Outcomes

Initial interventions evaluated included antiviral candidates remdesivir (an RNA polymerase inhibitor developed in collaboration with Gilead Sciences), the protease inhibitor combination lopinavir/ritonavir (investigated in trials sponsored by China CDC and others), the antimalarial hydroxychloroquine (previously studied for systemic lupus erythematosus), and immunomodulatory interferon beta-1a (used in multiple sclerosis). The platform also allowed assessment of adjunctive strategies and supportive care comparators informed by evidence from the RECOVERY trial and observational data from centers like Mount Sinai Health System. Primary outcome metrics mirrored endpoints used in trials by NIH Adaptive COVID-19 Treatment Trial and included all-cause mortality, need for mechanical ventilation, and time to clinical improvement. Secondary outcomes encompassed adverse events, renal replacement therapy initiation, and viral clearance assessed in substudies partnered with laboratories such as Pasteur Institute.

Results and Impact

Interim and final analyses led to early discontinuation of several arms after data showed no substantial mortality benefit: hydroxychloroquine and lopinavir/ritonavir were halted following signals consistent with null effect, and conclusions regarding interferon beta-1a were nuanced with subgroup considerations. Results aligned with contemporaneous findings from the RECOVERY trial and regulatory assessments by European Medicines Agency and U.S. Food and Drug Administration. The Solidarity dataset, encompassing thousands of participants across Argentina, Egypt, Philippines, and Russia, contributed to guideline revisions by organizations such as the World Health Organization and influenced prescribing patterns in ministries including Ministry of Health (Brazil), National Health Service (England), and Indian Council of Medical Research. Methodologically, the trial demonstrated feasibility of global adaptive platforms in pandemics, informing subsequent efforts by ACT Accelerator partners and shaping policy dialogues at the G20 and United Nations.

Ethical and Regulatory Considerations

The trial navigated expedited ethical review processes across diverse jurisdictions, engaging national ethics committees in South Africa, Peru, and Mexico while adhering to the Declaration of Helsinki and Good Clinical Practice standards from International Council for Harmonisation. Simplified trial procedures were critiqued and defended in light of obligations under instruments like the Nuremberg Code and guidance from the Council for International Organizations of Medical Sciences. Regulatory interactions included coordination with European Medicines Agency, U.S. Food and Drug Administration, and national drug regulatory authorities to reconcile emergency use policies and trial continuity. Data sharing commitments were coordinated with entities such as Wellcome Trust and Bill & Melinda Gates Foundation to promote transparency and rapid dissemination.

Criticisms and Controversies

Critics highlighted limitations including open-label design, heterogeneity of standard care across sites like Italy and Indonesia, and limited power for some subgroup analyses compared to platform trials like RECOVERY trial and investigator-initiated studies at Oxford University. Debates emerged over interpretation of null results for agents such as remdesivir and implications for emergency authorizations issued by U.S. Food and Drug Administration and national regulators. Questions about equitable access, trial representativeness in low-resource settings, and the role of industry partners including Gilead Sciences and policy actors like World Health Organization prompted scholarly discussion in forums associated with Lancet and New England Journal of Medicine. Despite controversies, Solidarity remains a pivotal example of global cooperative research during the COVID-19 pandemic and a precedent for future pandemic responses.

Category:Clinical trials